International Conference “Rhinology Unlimited”, Bulgaria

From November 21 to 23, 2025, the International Conference “Rhinology Unlimited” was held in Hisarya, Bulgaria, bringing together leading rhinology and otorhinolaryngology specialists from various countries. As part of the conference, on November 22, the Alpen Pharma scientific symposium took place, serving as a key platform for discussing modern approaches to the treatment of acute and chronic rhinosinusitis and for exchanging clinical experience. The symposium was attended by more than 140 participants, including leading experts from Bulgaria, Ukraine, Armenia, Kazakhstan, and Georgia.

The symposium featured keynote presentations by internationally renowned experts:

• Dr. Hideyuki Kawauchi (Japan) delivered a lecture titled “Inflammation of the Sinonasal Mucosa and the Clinical Impact of Cinnabsin.” He provided an in-depth overview of the mechanisms of nasal and paranasal sinus inflammation. The presentation also included experimental data from Prof. Oleg Melnikov (Ukraine), demonstrating the ability of the product to suppress IL-1β production by tonsillar cells. In addition, Dr. Kawauchi presented his own in vitro findings showing that Cinnabsin significantly reduces IL-8 release by activated A549 epithelial cells, indicating its anti-inflammatory potential.

• Prof. Diliana Vicheva, MD, PhD (Bulgaria) shared the results of a non-interventional study assessing the therapeutic effectiveness and safety of Cinnabsin in patients with acute or exacerbated chronic rhinosinusitis. The study demonstrated a significant reduction in acute rhinosinusitis symptoms, an excellent safety profile, and confirmed that Cinnabsin can be recommended for outpatient treatment regardless of concomitant therapy.

• Prof. Svitlana Levytska, MD, PhD (Ukraine) presented clinical data on the use of Cinnabsin in children with acute rhinosinusitis, emphasizing the importance of effective management of each disease episode. The high clinical effectiveness of the product— including symptom relief and faster recovery—was highlighted, supporting the inclusion of Cinnabsin in standard rhinosinusitis therapy.

The presentations not only generated considerable scientific interest but also underscored the practical significance of Cinnabsin, particularly in the context of mucosal inflammation control in patients with rhinosinusitis.

Additionally, Alpen Pharma hosted an informational exhibition booth where participants were able to explore scientific materials and evidence, take part in interactive activities, and win valuable branded gifts. In the evening, a festive and unforgettable carnival-style gala dinner was held, allowing participants to choose costumes and enjoy informal and cheerful communication. The evening program included an awards ceremony for the best speakers and leading ENT specialists, as well as a singing contest that helped strengthen professional connections among otorhinolaryngologists from different countries. The original event format created a unifying atmosphere and facilitated experience-sharing in a relaxed setting.

Such events are especially important for Cinnabsin, as they help demonstrate the scientific and clinical value of the product and support the strengthening of professional relationships among opinion leaders from various regions.